Embedded Files
Peer Reviewed Publications
Peer Reviewed Publications
Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma
npj Precision Oncology 2025
Aslı D. Munzur, Jack V. W. Bacon, Francine Fishbein, Cameron Herberts, Gráinne Donnellan, Cecily Q. Bernales, Karan Parekh, Gillian Vandekerkhove, David C. Müller, Yi Jou Ruby Liao, Maria Stephenson, Lucia Nappi, Daniel Khalaf, Corinne Maurice-Dror, Kim N. Chi, Bernhard J. Eigl, Christian Kollmannsberger, Maryam Soleimani & Alexander W. Wyatt
This study characterized clonal hematopoiesis in patients with advanced urological cancers and demonstrated how it can confound circulating tumor DNA genotyping. Matched white blood cell sequencing in clinical assays can overcome this issue.
AACR Cancer Research 2025
Joonatan Sipola, Aslı D. Munzur, Edmond M. Kwan, Clara C.Y. Seo, Benjamin J. Hauk, Karan Parekh, Yi Jou (Ruby) Liao, Cecily Q. Bernales, Gráinne Donnellan, Ingrid Bloise, Emily Fung, Sarah W.S. Ng, Gang Wang, Gillian Vandekerkhove, Matti Nykter, Matti Annala, Corinne Maurice-Dror, Kim N. Chi, Cameron Herberts, Alexander W. Wyatt, David Y. Takeda
Plasma cfDNA chromatin profiling developed in this study captured molecular phenotypes of metastatic prostate cancer and mechanisms of treatment resistance.
Clonal hematopoiesis after radioligand therapy in prostate cancer
TBD
Aslı D Munzur, Cameron Herberts, Edmond M Kwan, Louise Emmett, Shahneen Sandhu, James P Buteau, Amir Iravani, Anthony M Joshua, Roslyn J Francis, Sze-Ting Lee, Andrew M Scott, Andrew J Martin, Martin R Stockler, Alison Y Zhang, Scott G Williams, Cecily Q Bernales, Gráinne Donnellan, Melissa Koudjanian, Karan Parekh, Jack VW Bacon, Aly Karsan, Arun A Azad, Ian D Davis, Michael S Hofman, Alexander W Wyatt
In men with metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 promoted clonal hematopoiesis more frequently and strongly than cabazitaxel chemotherapy, particularly through expansion of PPM1D-mutant clones. This highlights the needs for longitudinal monitoring of hematologic risks.
The diverse effects of phenotypic dominance on hybrid fitness
Evolution 2022
Hilde Schneemann, Aslı D. Munzur, Ken A. Thompson, John J. Welch
By extending Fisher’s geometric model to include variable phenotypic dominance, this study shows that dominance commonly reduces F1 hybrid fitness, can mimic effects of uniparental inheritance, and explains patterns such as optimal outbreeding, environment-dependent heterosis, and occasional beneficial outcomes in hybrids.
Genome-resolved metagenomics of nitrogen cycling processes in Saanich Inlet
UJEMI 2021
Asli Munzur, Andrew Brown, Nicholas deGoutiere, Daniela Garcia, Lindsey Gross, Amy Lin
Genomic analysis shows Gammaproteobacteria-driven denitrification dominates in oxygen-depleted Saanich Inlet, driving nitrogen metabolism shifts and potentially increasing nitrous oxide emissions.
Adult‐type granulosa cell tumor of the ovary: a FOXL2‐centric disease
The Journal of Pathology: Clinical Research 2021
Jessica A Pilsworth, Dawn R Cochrane, Samantha J Neilson, Bahar H Moussavi, Daniel Lai, Aslı D Munzur, Janine Senz, Yi Kan Wang, Sina Zareian, Ali Bashashati, Adele Wong, Jacqueline Keul, Annette Staebler, Hannah S van Meurs, Hugo M Horlings, Stefan Kommoss, Friedrich Kommoss, Esther Oliva, Anniina EM Färkkilä, Blake Gilks, David G Huntsman
Whole-genome and targeted sequencing of adult-type granulosa cell tumors reveal that, beyond the nearly universal FOXL2 C402G mutation, additional somatic mutations—including in KMT2D—may underlie the clinical diversity and relapse risk of this ovarian cancer subtype.
Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours
Journal of Pathology 2021
Dawn R Cochrane, Kieran R Campbell, Kendall Greening, Germain C Ho, James Hopkins, Minh Bui, J Maxwell Douglas, Vassilena Sharlandjieva, Aslı D Munzur, Daniel Lai, Maya DeGrood, Evan W Gibbard, Samuel Leung, Niki Boyd, Angela S Cheng, Christine Chow, Jamie LP Lim, David A Farnell, Stefan Kommoss, Friedrich Kommoss, Andrew Roth, Lien Hoang, Jessica N McAlpine, Sohrab P Shah, David G Huntsman
Bioinformatic analysis of single-cell RNA-seq identified secretory and ciliated cell markers in endometrial tumors, linking their expression to survival and improved risk stratification. Journal cover letter by Asli Munzur.
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Nature 2025
Cameron Herberts, Matti Annala, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Anssi Nurminen, Olga V. Korhonen, Aslı D. Munzur, Kevin Beja, Elena Schönlau, Cecily Q. Bernales, Elie Ritch, Jack V. W. Bacon, Nathan A. Lack, Matti Nykter, Rahul Aggarwal, Eric J. Small, Martin E. Gleave, SU2C/PCF West Coast Prostate Cancer Dream Team, David A. Quigley, Felix Y. Feng, Kim N. Chi & Alexander W. Wyatt
Deep whole-genome sequencing of plasma and metastatic tissue in aggressive prostate cancer demonstrated that ctDNA comprises multiple evolving tumor populations, with resistance to androgen receptor inhibitors driven by convergent AR augmentation and nucleosome footprints enabling inference of gene expression from liquid biopsy.
Clinical Cancer Research 2025
G. Vandekerkhove, A.J. Murtha, D.C. Müller, M. Stephenson, K. Rostin, A.D. Munzur, C. Vasquez-Rios, J. Nikkola, J. Sipola, M. Annala, C. Herberts, E. Fung, J. Atwal, S. Al-Subaie, K. Parekh, C.Q. Bernales, G. Donnellan, D. Finch, K. Noonan, J.J. Ko, G. Ozgun, L. Nappi, C. Kollmannsberger, J.-M. Lavoie, S. Parimi, T. Todenhöfer, P. Ost, G. Wang, P.C. Black, C. Maurice-Dror, K.N. Chi, B.J. Eigl, A.W. Wyatt
In metastatic urothelial cancer, ctDNA and tissue sequencing showed high concordance for ERBB2 genotype but substantial spatiotemporal heterogeneity relative to HER2 IHC. This suggests in order to fully capture HER2/ERBB2 status for biomarker development integrating ctDNA with tissue- and protein-based assays is necessary.
Nature Cancer 2024
Evan W. Warner, Kim Van der Eecken, Andrew J. Murtha, Edmond M. Kwan, Cameron Herberts, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Nicolette M. Fonseca, Elie Ritch, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Aslı D. Munzur, Karan Parekh, Kevin Beja, Amanda Wong, Sofie Verbeke, Nicolaas Lumen, Jo Van Dorpe, Bram De Laere, Matti Annala, Gillian Vandekerkhove, Piet Ost & Alexander W. Wyatt
In de novo metastatic prostate cancer, extensive intra-prostate and metastatic heterogeneity led to discordant genotypes and inaccurate single-sample profiling, but pooling DNA from multiple biopsy cores improved detection of dominant disease. This offers a robust framework for genomics-guided treatment management.
Cancer Discovery 2025
Nofar Gumpert, Shira Sagie, Claudia Arnedo-Pac, Tomer Babu, Chen Weller, Abel Gonzalez-Perez, Yuan Wang, Lucas Michel Todó, Ronen Levy, Xi Chen, Polina Greenberg, Maria Dayan-Rubinov, Elizabeta Yakubovich, Talya Wasserman-Bartov, Mirie Zerbib, Jianhui Gong, Ryan J Rebernick, Anna Oliveira Tercero, Laura Agundez Muriel, Gil Benedek, Merav Kedmi, Roni Oren, Shifra Ben-Dor, Yishai Levin, Olga G Troyanskaya, Aslı D Munzur, Alexander W Wyatt, Marcin P Cieslik, David A Quigley, Eliezer M Van Allen, Niroshana Anandasabapathy, Joaquin Mateo, Xinbo Yang, Francisco Martínez-Jiménez, Nuria Lopez-Bigas, Yardena Samuels
New approaches that generate long-lasting therapeutic responses in therapy-resistant metastatic cancer patients are urgently needed. To address this challenge, we developed SpotNeoMet, a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients.
Perspective
Perspective
Clonal Hematopoiesis in Metastatic Urothelial and Renal Cell Carcinoma
Urotoday Beyond the Abstract 2025
Page updated
Google Sites
Report abuse